Tokyo, April 9 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000061197) titled 'Long-term outcomes of half-dose photodynamic therapy for chronic central serous chorioretinopathy' on April 8.
Study Type:
Observational
Primary Sponsor:
Institute - Nagoya University
Condition:
Condition - Chronic central serous chorioretinopathy
Classification by malignancy - Others
Genomic information - NO
Objective:
Narrative objectives1 - To clarify the long-term clinical course after half-dose photodynamic therapy in patients with chronic central serous chorioretinopathy and to consider appropriate treatment options for the future.
Basic objectives2 - Safety
Eligibility:
Age-lower limit - 20
years-old
=
Gender - Male and Female
Key inclusion criteria - Patients who underwent treatment with half-dose photodynamic therapy between January 1, 2015 and December 31, 2020.
Key exclusion criteria - Patients with a history of intravitreal injection or vitrectomy.
Target Size - 20
Recruitment Status:
Recruitment status - Preinitiation
Date of protocol fixation - 2026 Year 04 Month 01 Day
Anticipated trial start date - 2026 Year 04 Month 15 Day
Last follow-up date - 2028 Year 03 Month 31 Day
To know more, visit https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000070030
Disclaimer: Curated by HT Syndication.
